Ocugen(OCGN)2024-11-08 18:43Financial Performance - Ocugen closed 35 million in equity financing during Q3 2024, extending its cash runway into Q1 2026[9]. - Total cash and restricted cash as of September 30, 2024, was 39.5 million as of December 31, 2023[9]. - Total operating expenses for Q3 2024 were 16.1 million in Q3 2023, with R&D expenses at 8.1 million and G&A expenses at 6.3 million[10]. - The company reported a net loss of 11.72 million in Q3 2023[16]. - Total revenue for Q3 2024 was 3.70 million in Q3 2023[16]. Clinical Trials and Developments - The OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa is on track to complete enrollment in 1H2025, with an expanded access program allowing access to approximately 300,000 patients in the U.S., Canada, and Europe[2]. - OCU410 is currently in Phase 2 of the Phase 1/2 ArMaDa clinical trial, targeting geographic atrophy, which affects approximately 2-3 million people in the U.S. and EU[3]. - The FDA has approved the investigational new drug application for OCU200, with plans to initiate the Phase 1 clinical trial this quarter[8]. - The Data and Safety Monitoring Board approved enrollment for the second phase of the OCU410ST GARDian clinical trial[1]. - Ocugen plans to present new data on its clinical trials at an upcoming Clinical Showcase on November 12, 2024[6].